Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial.
Blonde L, Rosenstock J, Del Prato S, Henry R, Shehadeh N, Frias J, Niemoeller E, Souhami E, Ji C, Aroda VR. Blonde L, et al. Among authors: ji c. Diabetes Care. 2019 Nov;42(11):2108-2116. doi: 10.2337/dc19-1357. Epub 2019 Sep 17. Diabetes Care. 2019. PMID: 31530665 Clinical Trial.
Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
Rosenstock J, Blonde L, Aroda VR, Frias J, Souhami E, Ji C, Niemoeller E, Del Prato S. Rosenstock J, et al. Among authors: ji c. Diabetes Obes Metab. 2021 Jun;23(6):1331-1341. doi: 10.1111/dom.14345. Epub 2021 May 4. Diabetes Obes Metab. 2021. PMID: 33565209 Free PMC article.
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trial.
Davies MJ, Rosenstock J, Ali A, Russell-Jones D, Souhami E, Palmer K, Ji C, Niemoeller E, Skolnik N. Davies MJ, et al. Among authors: ji c. Diabetes Obes Metab. 2022 Jan;24(1):34-41. doi: 10.1111/dom.14543. Epub 2021 Oct 6. Diabetes Obes Metab. 2022. PMID: 34617398 Free PMC article. Clinical Trial.
Aggregation-enhanced photothermal therapy of organic dyes.
Yang M, Ji C, Yin M. Yang M, et al. Among authors: ji c. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 May-Jun;16(3):e1960. doi: 10.1002/wnan.1960. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024. PMID: 38695260 Review.
4,159 results